128 related articles for article (PubMed ID: 38376316)
1. Capecitabine is effective as palliative chemotherapy in a patient with androgen receptor and HER2 positive metastatic salivary duct carcinoma. A case report.
Čavka L; Zakotnik B
J Cancer Res Ther; 2023 Oct; 19(7):2048-2051. PubMed ID: 38376316
[TBL] [Abstract][Full Text] [Related]
2. Systemic therapy in the management of recurrent or metastatic salivary duct carcinoma: A systematic review.
Uijen MJM; Lassche G; van Engen-van Grunsven ACH; Tada Y; Verhaegh GW; Schalken JA; Driessen CML; van Herpen CML
Cancer Treat Rev; 2020 Sep; 89():102069. PubMed ID: 32717621
[TBL] [Abstract][Full Text] [Related]
3. Prediction of clinical benefit from androgen deprivation therapy in salivary duct carcinoma patients.
van Boxtel W; Verhaegh GW; van Engen-van Grunsven IA; van Strijp D; Kroeze LI; Ligtenberg MJ; van Zon HB; Hendriksen Y; Keizer D; van de Stolpe A; Schalken JA; van Herpen CM
Int J Cancer; 2020 Jun; 146(11):3196-3206. PubMed ID: 31745978
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant androgen deprivation therapy for poor-risk, androgen receptor-positive salivary duct carcinoma.
van Boxtel W; Locati LD; van Engen-van Grunsven ACH; Bergamini C; Jonker MA; Fiets E; Cavalieri S; Tooten S; Bos E; Quattrone P; Verhaegh GW; Schalken JA; Licitra L; van Herpen CML;
Eur J Cancer; 2019 Mar; 110():62-70. PubMed ID: 30771738
[TBL] [Abstract][Full Text] [Related]
5. Combination Chemohormonal Therapy in Metastatic Salivary Duct Carcinoma.
Jeong ISD; Moyers J; Thung I; Thinn MM
Am J Case Rep; 2020 Jun; 21():e925181. PubMed ID: 32601266
[TBL] [Abstract][Full Text] [Related]
6. Androgen receptor immunohistochemistry in salivary duct carcinoma: a retrospective study of 188 cases focusing on tumoral heterogeneity and temporal concordance.
Xu B; Dogan S; Haroon Al Rasheed MR; Ghossein R; Katabi N
Hum Pathol; 2019 Nov; 93():30-36. PubMed ID: 31430492
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma.
Masubuchi T; Tada Y; Maruya S; Osamura Y; Kamata SE; Miura K; Fushimi C; Takahashi H; Kawakita D; Kishimoto S; Nagao T
Int J Clin Oncol; 2015 Feb; 20(1):35-44. PubMed ID: 24553861
[TBL] [Abstract][Full Text] [Related]
8. Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas.
Park JC; Ma TM; Rooper L; Hembrough T; Foss RD; Schmitt NC; Sawhney R; Flanders A; Kang H
Head Neck; 2018 Dec; 40(12):E100-E106. PubMed ID: 30478962
[TBL] [Abstract][Full Text] [Related]
9. Novel therapeutic targets in salivary duct carcinoma uncovered by comprehensive molecular profiling.
Gargano SM; Senarathne W; Feldman R; Florento E; Stafford P; Swensen J; Vranic S; Gatalica Z
Cancer Med; 2019 Dec; 8(17):7322-7329. PubMed ID: 31609094
[TBL] [Abstract][Full Text] [Related]
10. Salivary duct carcinomas can be classified into luminal androgen receptor-positive, HER2 and basal-like phenotypes.
Di Palma S; Simpson RH; Marchiò C; Skálová A; Ungari M; Sandison A; Whitaker S; Parry S; Reis-Filho JS
Histopathology; 2012 Oct; 61(4):629-43. PubMed ID: 22882517
[TBL] [Abstract][Full Text] [Related]
11. Abiraterone in metastatic salivary duct carcinoma.
Urban D; Rischin D; Angel C; D'Costa I; Solomon B
J Natl Compr Canc Netw; 2015 Mar; 13(3):288-90. PubMed ID: 25736005
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy.
Yamamoto N; Minami S; Fujii M
Am J Otolaryngol; 2014; 35(6):731-5. PubMed ID: 25087467
[TBL] [Abstract][Full Text] [Related]
13. A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.
Boon E; Bel M; van Boxtel W; van der Graaf WTA; van Es RJJ; Eerenstein SEJ; Baatenburg de Jong RJ; van den Brekel MWM; van der Velden LA; Witjes MJH; Hoeben A; Willems SM; Bloemena E; Smit LA; Oosting SF; ; Jonker MA; Flucke UE; van Herpen CML
Int J Cancer; 2018 Aug; 143(4):758-766. PubMed ID: 29492965
[TBL] [Abstract][Full Text] [Related]
14. Combined androgen deprivation therapy in recurrent androgen-receptor-positive salivary duct carcinoma - a case report and review of the literature.
Poxleitner P; Shoumariyeh K; Steybe D; Hupfer V; Voss PJ; Rawluk J; Ermer M; Miething C; Schmelzeisen R; Duyster J
J Stomatol Oral Maxillofac Surg; 2020 Nov; 121(5):599-603. PubMed ID: 31904529
[TBL] [Abstract][Full Text] [Related]
15. [Effective treatment by both anti-androgen therapy and chemotherapy for a patient with advanced salivary duct carcinoma].
Kuroda H; Sakurai T; Yamada M; Uemura N; Ono M; Abe T; Fujii S; Maeda M; Kohda K; Obata M; Ando M; Iyama S; Kato J
Gan To Kagaku Ryoho; 2011 Apr; 38(4):627-30. PubMed ID: 21498992
[TBL] [Abstract][Full Text] [Related]
16. Sustained response of carcinoma ex pleomorphic adenoma treated with trastuzumab and capecitabine.
Sharon E; Kelly RJ; Szabo E
Head Neck Oncol; 2010 May; 2():12. PubMed ID: 20504363
[TBL] [Abstract][Full Text] [Related]
17. Expression pattern of androgen receptor and AR-V7 in androgen-deprivation therapy-naïve salivary duct carcinomas.
Yang RK; Zhao P; Lu C; Luo J; Hu R
Hum Pathol; 2019 Feb; 84():173-182. PubMed ID: 30267779
[TBL] [Abstract][Full Text] [Related]
18. Impact of postoperative radiotherapy and HER2/new overexpression in salivary duct carcinoma : A monocentric clinicopathologic analysis.
Haderlein M; Scherl C; Semrau S; Lettmaier S; Hecht M; Erber R; Iro H; Fietkau R; Agaimy A
Strahlenther Onkol; 2017 Nov; 193(11):961-970. PubMed ID: 28828496
[TBL] [Abstract][Full Text] [Related]
19. Trastuzumab for the treatment of salivary duct carcinoma.
Limaye SA; Posner MR; Krane JF; Fonfria M; Lorch JH; Dillon DA; Shreenivas AV; Tishler RB; Haddad RI
Oncologist; 2013; 18(3):294-300. PubMed ID: 23429737
[TBL] [Abstract][Full Text] [Related]
20. Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.
Boon E; van Boxtel W; Buter J; Baatenburg de Jong RJ; van Es RJJ; Bel M; Fiets E; Oosting SF; Slingerland M; Hoeben A; Tesselaar MET; Jonker MA; Flucke UE; ; van der Graaf WTA; van Herpen CML
Head Neck; 2018 Mar; 40(3):605-613. PubMed ID: 29272069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
